Related Experiment Video

Updated: Jan 13, 2026

The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

24.3K

Drug-coated balloons and diabetes: a review

Marco Frazzetto1,2, Sara Malakouti1, Bharat Khialani1,3

  • 1DCB Academy, Milan, Italy.

Cardiovascular Diabetology
|October 28, 2025
PubMed

Insights

Diabetes mellitus complicates coronary artery disease, increasing risks after percutaneous coronary intervention. Drug-coated balloons offer a promising scaffold-free alternative for diabetic patients undergoing PCI, potentially improving outcomes.

Area of Science:

  • Cardiology
  • Endocrinology
  • Biomedical Engineering

Background:

  • Diabetes mellitus (DM) significantly increases the risk and severity of coronary artery disease (CAD).
  • Diabetic patients face higher risks of adverse events and stent-related complications after percutaneous coronary intervention (PCI) compared to non-diabetic individuals.
  • Despite advancements in drug-eluting stents, long-term outcomes in diabetic patients remain a concern.

Purpose of the Study:

  • To review the impact of DM pathophysiology on PCI outcomes.
  • To explore the potential benefits of drug-coated balloons (DCB) in diabetic CAD patients.
  • To summarize current evidence comparing DCB to other PCI techniques and suggest individualized treatment approaches.

Main Methods:

  • Literature review of studies on DM, CAD, PCI, and DCB technology.
  • Analysis of the pathophysiological mechanisms linking DM to adverse cardiovascular events.
  • Synthesis of clinical trial data comparing DCB angioplasty with other revascularization strategies in diabetic patients.

Main Results:

  • DM is associated with more complex atherosclerosis and a pro-thrombotic, inflammatory state, worsening PCI outcomes.
  • Drug-coated balloons deliver antiproliferative agents directly to lesions without a metallic scaffold, offering a potential advantage.
  • Evidence comparing DCB to other PCI techniques in diabetic populations is still evolving, necessitating further research.

Conclusions:

  • DCB angioplasty presents a promising therapeutic option for diabetic patients with CAD, potentially mitigating risks associated with metallic stents.
  • Further research is needed to fully elucidate the long-term efficacy and optimal use of DCB in this high-risk population.
  • An individualized treatment strategy considering DM-specific factors is crucial for optimizing PCI outcomes in diabetic patients.

Keywords:
Coronary artery diseaseDiabetes mellitusDrug-coated balloonsDrug-eluting stentsPercutaneous coronary intervention

More Related Videos

A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application06:53

A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application

Published on: July 9, 2020

5.5K
Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery09:41

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery

Published on: December 23, 2014

17.0K

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
858
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
758
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.8K
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.0K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
789